๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers

โœ Scribed by Dr Bjorn Beermann; Alice E. Till; Hector J. Gomez; Martin Hichens; James A. Bolognese; Inga-Lill Junggren

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
553 KB
Volume
10
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis

When three intravenous doses of lisinopril were administered to healthy volunteers, area under the curve (to infinity) vs dose was linear with a positive intercept. Subtracting area under the extrapolated terminal phase of the serum profile from zero to infinity retained the linear relationship, but shifted the regression line to a zero intercept. It is postulated that the terminal phase reflects binding of drug to angiotensin-converting enzyme (ACE). The half-life for the terminal phase (approximately 40 h) was not predictive of steadystate parameters when ten daily doses (q24h) of lisinopril were administered orally to healthy volunteers. The mean effective half-life for accumulation was 126 h. The mean accumulation ratio was 1-38. Steady state was attained after the second daily dose. The observations in these studies with lisinopril are similar to those reported for enalaprilat, the active metabolite of the ACE inhibitor, enalapril maleate.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics and relative bioavailab
Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers
โœ Iftekhar Mahmood; Jacqueline S. Marinac; Sandra Willsie; William D. Mason ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 557 KB

## Abstract Selegiline is beneficial to Parkinsonian patients as an adjunct to levodopa therapy. A sensitive fluorimetric assay based on ibhibition of rat brain monoamine oxidaseโ€B (MAOโ€B) __in vitro__ has been developed to study the pharmacokinetics of selegiline. This method quantitates selegilin

Pharmacokinetics of oxatomide given perc
Pharmacokinetics of oxatomide given percutaneously to healthy volunteers
โœ Dr C. Benvenuti; M. Broggini; V. Botta; M. Valenti; G. Broccali; L. Dal Bo ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 321 KB

The percutaneous absorption of oxatomide gel at 5 per cent concentration was studied after single and repeated administration (85 mg b.i.d.) in six male and six female healthy volunteers, aged 25.750-8 years (mean kSEM) weighing 64-4k4.5 kg and the results compared with those obtained following a si

Pharmacokinetics of minoxidil in patient
Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers
โœ Marijke H. Adams; Wesley J. Poynor; William R. Garnett; H. T. Karnes; James J. F ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 246 KB ๐Ÿ‘ 2 views

Objectives: To determine the effect of reduced hepatic function on the pharmacokinetics of minoxidil. The pharmacokinetics of antipyrine, lorazepam, and indocyanine green were included as indicators of hepatic function. Methods: Eight mild cirrhotics and eight healthy subjects received antipyrine (p

Single dose pharmacokinetics and bioavai
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers
โœ Michael J. Lamson; John P. Sabo; Thomas R. Macgregor; Joseph W. Pav; Lois Rowlan ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB ๐Ÿ‘ 2 views

The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.